Clinical Trials
- Head and Neck Cancers, Phase 1 Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- Ages18 years and older
- GenderBoth
- Date05/10/2022
- Cancer, Gynecological Cancers, Head and Neck Cancers, Lung Cancer, Sarcoma Cancers
A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
- Date08/23/2021
- Head and Neck Cancers
A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)
- Date05/10/2022
- Head and Neck Cancers
A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
- Date05/10/2022
- Head and Neck Cancers, Stomach and Esophagus
A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA
- Date06/14/2022
- Head and Neck Cancers
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
- Ages18 years and older
- GenderBoth
- Date05/18/2022
- Bladder Cancer, Breast Cancer, Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Lung Cancer, Other Cancers, Pancreatic Cancer, Prostate Cancer, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
- Ages18 years and older
- GenderBoth
- Date06/13/2022
- Head and Neck Cancers
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
- Ages18 years and older
- GenderBoth
- Date05/10/2022
- Bladder Cancer, Brain and Other Nervous System Cancers, Breast Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Melanoma, Other Cancers, Pancreatic Cancer, Prostate Cancer, Sarcoma Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers, Lymphoma
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
- Ages18 years and older
- GenderBoth
- Date05/27/2022
- Bladder Cancer, Breast Cancer, Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Liver Cancer, Lung Cancer, Melanoma, Other Cancers, Pancreatic Cancer, Phase 1 Cancers, Prostate Cancer, Sarcoma Cancers, Stomach and Esophagus, Thyroid and Other Endocrine Cancers, Lymphoma
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
- Date04/27/2022